InnoCare Pharma Earnings Estimate
InnoCare Pharma Earnings per Share Projection vs Actual
About InnoCare Pharma Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of InnoCare Pharma earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current InnoCare Pharma estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as InnoCare Pharma fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.InnoCare Pharma Limited, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. The company was incorporated in 2015 and is headquartered in Beijing, China. Innocare Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 531 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in InnoCare Pink Sheet
InnoCare Pharma financial ratios help investors to determine whether InnoCare Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in InnoCare with respect to the benefits of owning InnoCare Pharma security.